Weeks, Dustin B.

From:PRPS SYSTEM NOTIFICATION [PRPS_Trial@uspto.gov]Sent:Thursday, January 21, 2016 3:50 AMTo:jblake@merchantgould.com; mfedowitz@merchantgould.com; Ettinger, Heather; Robinson,
Joseph R.; Weeks, Dustin B.; Ettinger, HeatherSubject:Party filing notice received - IPR2015-01093Attachments:webwbUSPTOSeal2.gif



UNITED STATES PATENT AND TRADEMARK OFFICE PATENT TRIAL AND APPEAL BOARD

Filing Courtesy Notice

Please note the following filing:

Case Number:	IPR2015-01093
Filer:	NPS Pharmaceuticals, Inc. of Bedminster, NJ
Filing Date:	1/21/2016

Document List			
Paper Name	Туре	Paper / Exhibit Number	
Transcript of Deposition of Anthony Palmieri III, Ph.D	Exhibit	2042	
CV of John F. Carpenter, Ph.D.	Exhibit	2043	
CV of Gordon Rausser, Ph.D.	Exhibit	2044	
Jackson 2012	Exhibit	2045	
Onoue 2004	Exhibit	2046	NDC Ex. 2150
U.S. Pharmacopeia 24,	Exhibit	2047	NPS Ex. 2158 CFAD v. NPS
OCKET			IPR2015-01093



Find authenticated court documents without watermarks at docketalarm.com.

Joshi 2012	E-1:1:4	2049
	Exhibit	2048
Fang 2012	Exhibit	2049
Blundell 1983	Exhibit	2050
Boesch 1978	Exhibit	2051
Akers 2002	Exhibit	2052
U.S. Pharmacopeia 788 (2011)	Exhibit	2053
Remington's Pharmaceutical Sciences, 18th Ed., 1549-51 (1990)	Exhibit	2054
U.S. Patent Publication No. 2013/0310314	Exhibit	2055
Annex1 Summary of Product Characteristics	Exhibit	2057
Orange Book Listing for Gattex	Exhibit	2058
Eli Lilly and Co. 2012	Exhibit	2059
Al-Hussein 2013	Exhibit	2060
Izutsu 2009	Exhibit	2061
U.S. Pharmacopeia 23, 1650-51 (1995)	Exhibit	2062
Center for Drug		
Evaluation and Research,		
Application	Exhibit	2063
Number203441Orig1s000	,	
Chemistry Review(s)		
FDA - Approved Drug	Exhibit	2064
Products Zorbtive	LAmon	2004
Shire 2015 - Shire		
Completes Acquisition of NPS Pharma	Exhibit	2065
Engellenner 2015 - Bass	F-1'1'4	2000
Goes Fishing	Exhibit	2066
Joseph Walker and Rob		
Copeland, New Hedge	Exhibit	2067
Fund Strategy WSJ	L'AIIIOIt	2007
Article_4.7.2015		
Wieczner 2015 - Why		
drug price controversey is	Exhibit	2068
great news for this hedge	Exmon	2000
fund manager		
Buchman 2006 - Etiology		
and Initial Management of	f Exhibit	2069
SBS		
Pirona 2015 - Espen	E-shihi	2070
endorsed recommendations	Exhibit	2070
O'Keefe 2006 - Short	Exhibit	2071
O RULL 2000 - SHULL		2071

bowel syndrome and intestinal failure		
Buchman 1997 - The		
Clinical Management of	Exhibit	2072
Short Bowel Syndrome		
NPS 2012 - Developing	T 1'1'	2072
orphan products for patients	Exhibit	2073
Hofstetter 2013 - Key		
Issues in Addressing The	Exhibit	2074
Clinical and Humanistic		
O'Keefe 2015 -		
Nutritional Issues in the	Exhibit	2076
SBS		
Tee 2011 - Emerging		
Treatment Options for SBS - Potential Role of	Exhibit	2077
Teduglutide		
Naberhuis 2015 -		
Teduglutide for Safe	Exhibit	2078
Reduction of Parenteral	EXIIIOII	2078
Nutrient		
Buchman 2012 -	Exhibit	2079
Teduglutide and SBS FDA - Approved Drug		
Products Zorbtive	Exhibit	2080
Crohn's and Colitis 2013 -		
Short Bowel Syndrome	Exhibit	2081
and Crohn's Disease		
Donohoe 2010 - Short	Exhibit	2082
Bowel Syndrome		
Zorbtive label	Exhibit	2083
Wales 2010 - Human growth hormone and	Exhibit	2084
glutamine	Exhibit	2004
Serono 2005 - Annual		2005
Report	Exhibit	2085
Part 1 Merck 2013 -	Exhibit	2086
Annual Report	Exhibit	2080
Part 2 Merck 2013 -	Exhibit	2086
Annual Report		
Keller 2004 - Management of the Short		
Bowel Syndrome after	Exhibit	2087
Extensive Small Bowel		
Resection		
Gattex label	Exhibit	2088
Oley Foundation 1994 -	Exhibit	2089
North American Home		

Parenteral NPS 2011 - NPS Pharmaceuticals Announces Completion of	Exhibit	2090
Treatment Phase in STEPS	LAHOR	2070
Seeking Alpha - CEO Discusses Q1 2013 Results	Exhibit	2091
Amiot 2013 - Determinants of home parenteral nutrition dependence	Exhibit	2092
McKeage 2015 - Teduglutide - A Guide to its Use in SBS	Exhibit	2093
FDA 2015 - Orange Book Approved Drug Products with Therapeutic Equivalence Evaluations	Exhibit	2094
Jeppesen 2014 - Spectrum of short bowel syndrome in adults - Intestinal insufficiency to intestinal failure	Exhibit	2095
AGA 2003 - Technical Review on Short Bowl Syndrome and Intestinal Transplantation	Exhibit	2096
Jeppesen 1999 - Quality of life in patients receiving home parenteral nutrition	Exhibit	2097
Jeppesen 2011 - Randomised placebo- controlled trial of teduglutide in	Exhibit	2098
ADA 2013 - Economic Cost of Diabetes in the US in 2012	Exhibit	2099
Rodrigues 2011 - Short Bowel Syndrome	Exhibit	2100
Thompson 2012 - Current Management of SBS Jeppesen 2012 -	Exhibit	2101
Teduglutide Reduces Need for Parenteral Support Among Patients with SBS	Exhibit	2102

Seeking Alpha - CEO Discusses Q2 2013 Results	Exhibit	2103
Seeking Alpha - CEO		
Discusses Q3 2013	Exhibit	2104
Results		
Seeking Alpha - CEO Discusses Q4 2013	Exhibit	2105
Results		
Shire 2015 - Q3 2015 Results	Exhibit	2106
Shire 2015 - Q3 2015		0 10 7
Results	Exhibit	2107
Wolters Kluwer Price	T 1'1'	0100
Data	Exhibit	2108
NPS Pharmaceuticals'		
(NPSP) CEO Francois	E-1:11:4	2100
Nader on Q1 2014 Results	Exhibit	2109
- Earnings Call Transcript		
Seeking Alpha - CEO		
Francois Nader on Q2	Exhibit	2110
2014 Results		
Seeking Alpha - CEO		
Francois Nader on Q3	Exhibit	2111
2014 Results		
NPS 2014 10-K	Exhibit	2112
Shire 2015 - Q1 2015		
Results	Exhibit	2113
Shire 2015 - Q2 2015		
results	Exhibit	2114
Shire 2015 - SHPG		
Flemming Ornskov on Q3		
2015 Results - Earnings	Exhibit	2115
Call Transcript		
Seeking Alpha 2013 -		
NPS Pharmaceuticals	Exhibit	2116
CEO Discusses		
Yahoo Finance - NPSP		0115
Historical Prices	Exhibit	2117
NPS 2013 10-K	Exhibit	2118
Moon 2014 - Biotech		-
selloff could be harbinger	Exhibit	2119
of further decline Reuters		
Ashton 2014 - Biotech		
Sell Off Drags NASDAQ-		
100 Down To 2-Year	Exhibit	2120
Lows		
Nasdaq - Overview for	E 1'1'	0101
NRI	Exhibit	2121

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.